相关实验视频

Updated: Jan 15, 2026

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody

Published on: May 16, 2020

通过小分子抑制剂向人类B型淋巴瘤中的RAB7,阻止瘤细胞生长

Maria Fernandez¹, Rui Wang¹, Jingwei Wang¹

¹Department of Microbiology, Immunology and Molecular Genetics, Joe R. & Teresa Lozano Long School of Medicine, The University of Texas at San Antonio, San Antonio, TX, United States.

Frontiers in oncology

|October 8, 2025

概括

准RAB7,一个参与内体成熟的小GTPase,显示出治疗成熟B细胞淋巴瘤的前景. 在临床前模型中,抑制RAB7显著降低了淋巴瘤细胞生长和瘤发育.

科学领域:

分子生物学分子生物学
在瘤学瘤学.
免疫学免疫学免疫学

背景情况:

RAB7 (RAB7A/Rab7) 是一个小GTPase,对内分体成熟和B细胞中NF-κB激活至关重要.
RAB7在抗体反应中发挥作用,并与B细胞信号通路有关.

研究的目的:

研究RAB7在成熟的B细胞衍生淋巴瘤中的作用,包括扩散性大B细胞淋巴瘤 (DLBCL) 和伯基特淋巴瘤.
在临床前淋巴瘤模型中评估选择性小分子RAB7抑制剂CID1067700的治疗潜力.

主要方法:

在初级DLBCL和淋巴瘤细胞系中分析RAB7A转录表达.
用CID1067700治疗淋巴瘤细胞系,评估细胞生长,增殖和存活率.
在使用伯基特淋巴瘤细胞的异种移植小鼠模型中评估CID1067700的疗效.

主要成果:

RAB7A转录在DLBCL中表达,RAB7蛋白在激活的B细胞和淋巴瘤细胞系中升高.
CID1067700治疗以剂量依赖的方式抑制了淋巴瘤细胞的生长,增殖和存活率.
在体内,CID1067700抑制了瘤的发展,其效果因脂质的破坏和BCL6抑制而增强.

结论:

高RAB7A表达与DLBCL患者的不良预后相关.
用像CID1067700这样的抑制剂向RAB7代表了成熟B细胞淋巴瘤的有希望的治疗策略.
联合抑制RAB7和BCL6可能会提高治疗这些恶性瘤的疗效.

关键词:

这是一种B细胞淋巴瘤.伯基特淋巴瘤是一种淋巴瘤在CID1067700700中使用.FX1 FX1 的意思是什么?在MβCD中,MβCD是MβCD.这就是NF-κBB.在RAB7中,RAB7是指RAB7.扩散大的B细胞淋巴瘤.

更多相关视频

Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma

Tumor Engraftment in a Xenograft Mouse Model of Human Mantle Cell Lymphoma

Published on: March 30, 2018

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics

Published on: May 14, 2016

相关概念视频

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Inhibition of Cdk Activity

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...